Stock Events

Stock Events

Viridian Therapeutics 

$19.31
20
-$0.25-1.28% Today

Statistics

Day High
19.74
Day Low
19
52W High
34.29
52W Low
9.9
Volume
683,841
Avg. Volume
1,690,550
Mkt Cap
1.97B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.15
-0.88
-0.61
-0.34
Expected EPS
-1.079492
Actual EPS
N/A

Financials

-483.57%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
141.7MRevenue
-685.2MNet Income

Analyst Ratings

$37.60Average Price Target
The highest estimate is 61.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
91%
Hold
9%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRDN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on treatments for eye diseases, allergic and inflammatory diseases, which overlaps with Viridian's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the discovery, development, and commercialization of therapeutics in areas such as viral diseases, inflammatory and fibrotic diseases, which can compete with Viridian's product pipeline.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals focuses on creating new possibilities in medicine to cure diseases and improve people's lives, including treatments for cystic fibrosis, competing in the biotech space with Viridian.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotechnology pioneer that discovers, develops, manufactures, and delivers innovative human therapeutics, including treatments for inflammatory diseases, which competes with Viridian's focus areas.
Biogen
BIIB
Mkt Cap22.63B
Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, competing with Viridian in the biopharmaceutical sector.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie's business is focused on delivering transformative therapies in areas such as immunology and oncology, which can compete with Viridian's therapeutic development programs.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care, but also has a growing presence in biopharmaceuticals that could compete with Viridian.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a broad portfolio in various therapeutic areas, including respiratory, cardiovascular, and oncology, potentially competing with Viridian's focus on innovative therapeutics.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global biopharmaceutical company that develops and manufactures healthcare products including medicines and vaccines for a wide range of conditions, competing with Viridian in the healthcare sector.
Merck
MRK
Mkt Cap214.76B
Merck operates globally and offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, competing with Viridian in the pharmaceutical and healthcare market.

About

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
Mr. Stephen F. Mahoney J.D., MBA
Employees
143
Country
US
ISIN
US92790C1045

Listings

LSE
GB
0K1R.LSE
XNAS
US
VRDN
F
DE
1S1.F
BOATS
BOATS
VRDN.BOATS

0 Comments

Share your thoughts

FAQ

What is Viridian Therapeutics stock price today?▼
The current price of VRDN is $19.31 USD — it has decreased by -1.28% in the past 24 hours. Watch Viridian Therapeutics stock price performance more closely on the chart.
What is Viridian Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Viridian Therapeutics stocks are traded under the ticker VRDN.
Is Viridian Therapeutics stock price growing?▼
VRDN stock has fallen by -31.78% compared to the previous week, the month change is a -34.17% fall, over the last year Viridian Therapeutics has showed a +53.98% increase.
What is Viridian Therapeutics market cap?▼
Today Viridian Therapeutics has the market capitalization of 1.97B
When is the next Viridian Therapeutics earnings date?▼
Viridian Therapeutics is going to release the next earnings report on May 12, 2026.
What were Viridian Therapeutics earnings last quarter?▼
VRDN earnings for the last quarter are -1.08 USD per share, whereas the estimation was -0.98 USD resulting in a -10.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Viridian Therapeutics revenue for the last year?▼
Viridian Therapeutics revenue for the last year amounts to 141.7M USD.
What is Viridian Therapeutics net income for the last year?▼
VRDN net income for the last year is -685.2M USD.
How many employees does Viridian Therapeutics have?▼
As of April 01, 2026, the company has 143 employees.
In which sector is Viridian Therapeutics located?▼
Viridian Therapeutics operates in the Health Care sector.
When did Viridian Therapeutics complete a stock split?▼
The last stock split for Viridian Therapeutics was on November 13, 2020 with a ratio of 1:15.
Where is Viridian Therapeutics headquartered?▼
Viridian Therapeutics is headquartered in Waltham, US.